Page 83 - Resúmen - XXV Congreso Latinoamericano de Parasitología - FLAP

CM-12

Sinthetic alpha- Gal glycotopes as vacccines and therapeutic biomarkers for

Chagas disease and leishmaniasis

(Glicotopos sintéticos de alpha-gal como vacunas y biomarcadores terapéuticos en la enfermedad de
Chagas y leishmaniosis)

1,*
1,*
1,*
Susana Portillo , Igor E. Silva , Uriel Rodriguez-Ortega , Alba Montoya , Sayonara
2,*
3
1
1
2
1
M. Viana , Brenda G. Zepeda , Eva A. Iniguez , Roger A. Ashmus , Jerry A. Duran ,
1
2
1
Nathaniel S. Schocker , Janet J. Olivas , Nasim H. Karimi , Alexandre F. Marques ,
1,4
5
5
1
5
Julio Alonso-Padilla , Luis Izquierdo , Maria-Jesús Pinazo , Maria Tays Mendes ,
Cameron C. Ellis , Claudia Manriquez Roman , Jane F. VandeBerg , Otacilio C. Moreira
1
1
6
8
9
7 , Laura-Isobel McCall , Belkisyolé Alarcón de Noya , Oscar Noya , John L. VandeBerg
9
3
6 , Augusto M. Carvalho Aldina Barral , Rosa A. Maldonado , Camila I. de Oliveira ,
1
3,
3
Faustino Torrico , Joaquim Gascón , Katja Michael , and Igor C. Almeida
5
10
1,¶
2
1 Border Biomedical Research Center, Department of Biological Sciences, University of Texas at El Paso,

El Paso, TX, U.S.A.; Department of Chemistry and Biochemistry, University of Texas at El Paso, El Paso,
2
4
TX, U.S.A.; Instituto Gonçalo Muniz, FIOCRUZ, Salvador, Bahia, Brazil; Departamento de Parasitologia,
3
Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil;
5
Barcelona Centre for International Health Research (ISGlobal), Barcelona, Spain; University of Texas Rio
6
Grande Valley, Edinburg, TX, U.S.A.; Laboratório de Biologia Molecular e Doenças Endêmicas, Fundação
7
Oswaldo Cruz, Rio de Janeiro, Brazil; University of Oklahoma, Norman, OK, U.S.A.; Instituto de Medicina
9
8
10
Tropical, Facultad de Medicina, Universidad Central de Venezuela, Caracas, Venezuela; Fundación
CEADES and Universidad Mayor de San Simón, Faculty of Medicine, Cochabamba, Bolivia;
¶
* Equally contributing authors; corresponding author: icalmeida@utep.edu

Chagas disease (CD), caused by Trypanosoma cruzi, affects 6-7 million people in Latin America. The great
majority of those infected with T. cruzi are asymptomatic; however, 20-30% will develop cardiac and/or
gastrointestinal complications, leading to death or permanent disability. Infected individuals can now be
found in many other parts of the world, including the U.S.A., Europe, and Japan, due to intense globalized
migration in the last several years. Currently, there are two drugs available to treat CD, benznidazole and
nifurtimox, which are primarily used in endemic countries in Latin America. While both drugs are highly
effective in the acute stage of the infection, they are less effective for the treatment of chronic stage.
Moreover, chemotherapy with these drugs is also linked with serious adverse events, which may lead to
the discontinuation of the treatment in 10-20% of the patients. Furthermore, negative seroconversion using
conventional serology following chemotherapy takes 10-20 years to occur, which is a poor outcome to
support an extensive treatment program of chronic CD patients. Due to these and other reasons, it is
estimated that less than 1% of chronic CD patients currently undergo chemotherapy. Therefore, dearth of
dependable biomarkers (BMKs) for assessment of therapeutic efficacy following chemotherapy is a major
challenge in translational CD. Other major challenges include the lack of effective epidemiological and
insect vector control, accurate diagnosis (particularly in nonendemic areas like the U.S., and endemic areas
like Mexico), and a prophylactic or therapeutic vaccine. T. cruzi infective trypomastigote forms have a
surface heavily coated with highly immunogenic glycosylphosphatidylinositol (GPI)-anchored glycoproteins
such as tGPI-mucins (or TcMUCII mucins), mucin-associated proteins (MASP), and trans-sialidases (TS).

81
RESÚMENES DE charlas magistrales